Skip to main content
XAIR
NASDAQ Life Sciences

Beyond Air 子公司报告令人信服的早期疗效和有利的安全性在 1 期癌症试验中

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
9
Price
$0.954
Mkt Cap
$8.476M
52W Low
$0.673
52W High
$6.44
Market data snapshot near publication time

summarizeSummary

Beyond Air 的子公司 Beyond Cancer, Ltd. 宣布了其 1 期 UNO 实验的积极中期数据，该实验针对实体瘤，展示了早期临床活性和有利的安全性特征。该试验涉及十名接受过大量预处理的末期癌症患者，结果显示七名患者在治疗后 19 至 37 个月仍然存活，其中两名三重阴性乳腺癌患者没有疾病证据。这对于这个小盘生物技术公司来说是一个非常重要的发展，特别是在最近的“持续经营”警告之下，这样的令人信服的早期疗效和安全性数据对于吸引进一步的投资和推进该计划至关重要。这些数据将在四月的 AACR 年会上呈现，投资者将密切关注公司关于后续临床试验阶段的计划。

在该公告发布时，XAIR的交易价格为$0.95，交易所为NASDAQ，所属行业为Life Sciences，市值约为$847.6万。 52周交易区间为$0.67至$6.44。 这则新闻被评估为积极市场情绪，重要性评分为9/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed XAIR - Latest Insights

XAIR
Apr 24, 2026, 4:30 PM EDT
Filing Type: PRE 14A
Importance Score:
9
Beyond Air Seeks Second Reverse Stock Split to Avoid Nasdaq Delisting, Warns of Total Investment Loss
Sentiment: Negative
View Wiseek Article
XAIR
Apr 15, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
8
Beyond Air Appeals Nasdaq Delisting Notice, Securing Temporary Stay Until May Hearing
Sentiment: Neutral
View Wiseek Article
XAIR
Apr 10, 2026, 4:33 PM EDT
Source: Wiseek News
Importance Score:
9
Beyond Air Faces Nasdaq Delisting Threat Over Sub-$1 Share Price, Plans Appeal
Sentiment: Negative
View Wiseek Article
XAIR
Apr 10, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
9
Beyond Air Faces Imminent Nasdaq Delisting Threat, Ineligible for Standard Compliance Period
Sentiment: Negative
View Wiseek Article
XAIR
Apr 01, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Beyond Air Announces CEO Transition with Substantial Severance Amidst Going Concern Warning
Sentiment: Negative
View Wiseek Article
XAIR
Apr 01, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Beyond Air Secures Major GPO Deal, Expanding LungFit PH Access to 2,000 Hospitals
Sentiment: Positive
View Wiseek Article
XAIR
Mar 17, 2026, 4:35 PM EDT
Source: GlobeNewswire
Importance Score:
9
Beyond Air Subsidiary Reports Compelling Early Efficacy, Favorable Safety in Phase 1 Cancer Trial
Sentiment: Positive
View Wiseek Article
XAIR
Feb 13, 2026, 4:01 PM EST
Filing Type: 10-Q
Importance Score:
9
Beyond Air Reports Q3 Results with Going Concern Warning, Details Recent Capital Raises and Strategic Divestiture
Sentiment: Neutral
View Wiseek Article
XAIR
Feb 10, 2026, 9:00 AM EST
Filing Type: 424B3
Importance Score:
8
Beyond Air Finalizes Registration for Resale of 7.86 Million Shares and Warrants
Sentiment: Negative
View Wiseek Article
XAIR
Feb 02, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
8
Stockholders Approve Equity Incentive Plan, Authorizing 850,000 New Shares
Sentiment: Negative
View Wiseek Article